Welcome To Our Website
The Order of Knights of Pythias is an international, non-sectarian fraternal order, established in 1864
in Washington, DC, and was the first fraternal order to be chartered by an
Act of Congress. It’s aim was to heal the wounds of the Civil War between the North and South and
promote friendship among men and relieve suffering.
Today in addition to doing charitable work, we sponsor dances, fundraising events
and socials for members and guests.
News and Updates
Now the 109-year-old family owned business in LaFayette is turning toward a new venture: Cannabis.
After planting a test crop of industrial hemp (a type of cannabis) last year, and an aborted attempt to make a CBD-infused beverage product, the company this month is launching a new division called Beak & Skiff Research.
Its mission will be to develop a hemp-growing and processing program. It will produce cannabis-derived CBD, both in a crude bulk form and in more refined “distillates” that can be used to make oils for salves, tinctures and ointments that are touted by advocates for their health effects.
Eventually, the company hopes to be able to make CBD-infused beverages to add to their existing drinks line, when that becomes legal.
“Innovation is in our DNA,” Beak & Skiff president Eddie Brennan said. “We’re always talking about diversification on our farms, to help balance the ups and downs of the apple business.”
Since the coronavirus emergency, for example, the company has turned its 1911 Established Distillery on Route 20 into one of the largest local producers of alcohol-based hand sanitizer.
The new move to cannabis not only comes amid the uncertainty of the coronavirus pandemic, but also during a lingering lack of clarity on the cannabis/CBD industry in New York and the rest of the country.
A law signed by Gov. Andrew Cuomo in December established new guidelines for the legal growing and manufacturing of hemp and hemp extracts, including CBD.
But the law did not legalize adding CBD to foods and beverages — a practice that remains common in the state despite its illegal status. CBD (cannabidiol) extracted from hemp is a non-psychoactive compound.
Last year, Beak & Skiff started a 3-acre test plot of industrial hemp on its sprawling property near the intersection of Route 20 and 80 in LaFayette. It also produced a new product, CBD Cold Brew Coffee, made with CBD from another nearby processor.
But that product had to be pulled when the state Department of Agriculture and Markets issued guidelines making the manufacture and sale of CBD in food and drink illegal. The state said it was acting according to rulings from the U.S. Food and Drug Administration.
Cuomo promised late last year to convene experts in the field early this year to address the future of the hemp, CBD and cannabis industries. That has apparently been derailed by the coronavirus pandemic.
Nevertheless, Beak & Skiff has decided to move ahead, planting a new 20 to 25 acres of industrial hemp. It’s also building a dedicated new facility to process the hemp into usable oils.
Starting this fall, Beak & Skiff will offer its facility to other hemp growers for processing, while also working on its own products, Brennan said. It hopes to have Beak & Skiff-branded tincture and lotions available later this year.
CBD-infused drinks may come in the future.
“We’re excited by where this is headed, despite some bumps along the way,” Brennan said. “We hope there is a path to putting this into food and drink when we can do it legally and ensure the highest quality.”
Note to readers: if you purchase something through one of our affiliate links we may earn a commission.
The Covid outbreak and its fallout on the cannabis and CBD markets are under intense scrutiny by industry observers. Commercial closures, rampant anxiety and focus on self-care are only some of the factors driving shifts in consumer behaviors. Particularly for the overcrowded CBD market, these changes have far-reaching implications.
With millions of jobless and the greatest recession in US history looming on the horizon, consumers are tightening their belts and looking for value in their self-care products. CBD companies are taking note and, with brick and mortar outlets shuttered, they are moving online with deals to attract the budget-conscious consumer. This spells good news for older adult CBD enthusiasts.
I emailed and spoke on the phone with Virginia Lee, CBD Research Manager at the Chicago-based Brightfield Group, about the CBD consumption patterns of Baby Boomers and elder adults, and how they are positioned to benefit from this new price-slashing trend.
Because boomers’ awareness of CBD’s health benefits is growing, Lee explained, many are shifting from trial use to becoming daily users. In fact, the number of boomers who reported using CBD 5 or more times per week rose from 36% in 2019 to over half (56%) in 2020, according to Brightfield Group’s consumer insights. They also found that 19% of boomer CBD consumers reported using CBD multiple times per day.
When questioned during the period from March 16-19, 27% of CBD-using boomers answered that they expected to use more CBD during the Covid-19 crisis.
CBD During Covid
The CBD space was already glutted before the pandemic hit, but the coronavirus may do its own form of Darwinian winnowing. Writing about COVID’s effects on the CBD market in the Brightfield Group blog, Managing Director, Bethany Gomez, explains:
Smaller brands often rely on small or local retailers to distribute the bulk of their products. In the current environment, mass shuttering of retailers around the country is likely to deal a death blow to many of the smaller brands in the market. This could actually work in the favor of many of the larger brands, who are better positioned to weather the storm and be able to support a robust e-comm strategy. If they can keep the lights on over the next few months, they may be competing in a much less crowded field once we emerge from the crisis.”
Part of that e-comm strategy is to offer budget-conscious consumers the CBD offers they are looking for. Boomers take note!
Price Reductions and Free Shipping
Most of us aren’t used to seeing CBD products other than lip balms sold for under $10. But for a few days in May, Bluebird Botanicals offered 40% off its Classic CBD Oil (1/3 oz originally priced at $12.95) for $7.77.
To celebrate International Day of Families, CBDMEDIC is offering a buy-1-get-1-free product offer during May, along with a free hand sanitizer and free shipping in the US.
KoiCBD is also offering a limited-time-only buy-1-get-1-free with certain products.
Lee provides some insight from CBD industry leader Charlotte’s Web:
“Charlotte’s Web in its May 14, 2020 Q1 2020 earnings call stated that they had reduced their list prices across their portfolio by 15 to 20% in DTC (Direct-to-Consumer) and B2B in late March/April… Among the 7 topicals they launched in April, 3 are priced at $14.99.”
On the Charlotte’s Web website, signing up with your email will get you a 10% discount on your first order.
For those running low on CBD, now’s a good time to let your fingers do the walking – and if you are a boomer, you’ll know what mean.
The news comes just over a week after Aurora divulged that it and Reliva had agreed to the acquisition. The basic terms of the deal are that Aurora is to pay $40 million in common stock for Reliva, with potentially as much as $45 million more if the latter hits certain financial incentives across the following two years. Those additional monies, if earned, will be paid either in cash, stock, or a combination of the two.
A field of hemp, which provides the CBD for Reliva’s products. Image source: Getty Images.
This is lightning-fast for the marijuana industry, in which acquisitions have often taken (and are taking) many months to close.
Since Reliva was a privately held company before being absorbed into Aurora, it did not make its finances public. According to an article on MarketWatch, it books $13 million to $14 million in revenue per year. Aurora did say that its new asset “is expected to be Adjusted EBITDA accretive to Aurora shareholders in fiscal 2020 and fiscal 2021.” No mention was made of Reliva’s net profit or loss.
The impetus behind the marijuana company‘s purchase is to gain a major CBD asset based in the huge U.S. market (Aurora is headquartered in Canada). The company said Reliva’s products are sold in more than 20,000 retail locations and online. It added that Reliva has contracts with a host of retailers in the U.S., including eight of the country’s top 20 convenience store operators.
The news of the deal’s closure helped lift Aurora shares on Thursday. In contrast to the declines of the major stock indexes, they increased by nearly 0.3% on the day.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>
The weekend is here! Put yourself a mug of French Guatemalan coffee, get a seat by the swimming pool, and prepare yourself for our longer kind weekend checks out:
– No One Really Knows ( The Better Letter)
– Inside Kylie Jenner’s Web Of Lies– And Why She’s No Longer A Billionaire ( Forbes)
– Pandemics & Markets: Part II ( Financier Amnesia)
– The Future of ETFs, and Why Sustainable-Investing Indexes Will Be a Trillion-Dollar Service ( Barron’s)
– A Surprise Origin Story of the CBD Craze ( New York City Times)
– Amazon’s Big Breakdown: The pandemic briefly brought the Whatever Store to its knees– by prematurely producing a future it has actually long been preparing for. ( New York Times)
– We Are All The Burnout Generation ( Zander Nethercutt)
– Jonathan Haidt Is Attempting to Heal America’s Divisions ( The Atlantic)
– The Remaking of Steve Buscemi ( GQ)
– Fiona Apple’s Art of Radical Sensitivity ( New Yorker)
Make certain to check out our Masters in Service interview this weekend with David Rosenberg of Rosenberg Research Rosie is best understood for his calls as Chief Economist of Merrill Lynch in the 1990 s and 2000 s.
The epic battle against coronavirus false information and conspiracy theories
Welcome to Cultivated, our weekly newsletter where we’re bringing you an inside take a look at the deals, trends, and characters driving the multibillion-dollar global marijuana boom.
Delighted Friday everybody,
It’s been rather a hectic week here as I got my feet under me, returning back to my “normal” beat. I take pride in the work Yeji and I did– along with guidance from my editor Zach– on our deep dive into Eaze’s scaled-back ambitions from 2017 to now
The startup’s ups and downs over the past three years supply insight into the wild ride that cannabis startups, financiers, and workers have actually been on since US states began legalizing the drug.
The other huge piece of news this week was Canopy Growth’s depressing profits
” More stressing for us were remarks around the need to ‘comprehend what consumers want’.
That being stated, Canopy Development is still the biggest cannabis business. And with a deep-pocketed alcohol giant backing the business– together with a brand-new( ish) CEO, David Klein– it’s probably not time to count them out yet.
I’ll be talking to Klein later on this afternoon as well.
Here’s what we wrote about:
An inside take a look at Eaze’s newest pitch deck reveals vastly downsized ambitions from the once-soaring marijuana startup
Internal files and interviews reveal Eaze’s vastly scaled-back aspirations. In 2017, Eaze– then a marijuana delivery service– predicted that it would sell $1 billion worth of marijuana on the platform and aggressively expand to brand-new states.
In 2020, under the guidance of a brand-new executive team and after a round of layoffs, Eaze has pared back that expectation to $190 million in sales.
We took a deep dive into the company’s financial forecasts from 2017 to today and published its complete 2020 pitch deck.
Cannabis startup Caliva laid off 20 employees consisting of a top retail exec as headwinds from the coronavirus pandemic upend the market
Marijuana startup Caliva laid off 20 workers from its corporate office on March 30, the company verified.
The cuts mostly affected workers in the retail management division and consisted of Elizabeth Cooksey, a senior officer who was generated to drive Caliva’s retail method in 2019
- Red Light Holland, a CSE-listed psychedelics business that is planning to produce and offer branded “magic truffles” in the Netherlands, has actually appointed comic Russell Peters as its Chief Creative Officer Former Canopy Growth CEO Bruce Linton is the company’s advisory chair.
- CSE-listed TerrAscend closed a $37 million personal placement on Friday. The deal was upsized from $30 million, and investors include Jason Karp, the creator of Tourbillon Capital Partners and CEO of HumanCo. TerrAscend reported earnings on Thursday with $348 million in net sales in Q1 2020.
A surprise origin story of the CBD craze(New York City Times)
‘There Is An Active Conversation Of CBD Happening Across The Nation,’ Says A New Report. Which Spells Opportunity.
In 2017, when celebrity host ( The View) Whoopi Goldberg was delighting in the peak of her then-new CBD brand name, Maya & Whoopi, a press reporter asked what the next action was. “World supremacy,” Goldberg joked at the time.
She may have been onto something.
Goldberg this year parted methods with her organisation partner, Maya Elisabeth; the result was that their company folded. However if Goldberg back in 2017 was predicting a huge future for CBD startups, she wasn’t off the mark, judging from a the findings of a new survey from New Frontier Data.
” The newness of the CBD experience for many customers recommends there remains considerable chance for well-developed brands to bring in customer attention and capture market share from existing market leaders,” the report says. A big reason why start-ups might have an edge, the scientists suggest? The novelty element.
” Customers have not been utilizing the items with adequate longevity to produce long lasting brand name commitment that is challenging to remove,” the report says.
To compile the research study, New Frontier Data surveyed 4,074 U.S. adults in mid-March. The survey population consisted of 26%of subjects who made less than $30,000; 27%making $39,000 to $59,999; 27
ning $60,000 to $89,999; and 16%making $90,000 and up.
Amongst the report’s chief takeaways:
Familiarity with CBD is an essential aspect
Some 86%of those surveyed had actually heard of CBD, and a majority (55%) were interested in finding out more.
Â· Word of mouth is a typical thread: Almost 3 in 4 (73%) of those surveyed who ‘d heard of CBD reported having had a discussion about it, consisting of the 67%who had actually not consumed it. Individuals reported that their discussions were largely favorable.
Â· Favorable associations: 51%of those surveyed knew a good friend or relative who ‘d utilized CBD, and almost 1 in 5 (17%) had suggested CBD to somebody else.
Â· Frequency: Among Americans who reported ever having actually consumed CBD, 40%stated they did so a minimum of once a week, with older consumers utilizing it more regularly than more youthful ones.
Â· CBD customers seem to be evangelists A majority, 56%, said they had actually suggested CBD items to another person.
Tension and pain are significant factors for usage
Â· 3 in 5 (60%) of customers surveyed reported utilizing CBD in a context that may be called “unwinding,” such as relaxation, relief of stress or anxiety reduction. The main usage, however (41%), was pain management.
Way of Intake
Â· Oils and casts led the way, at 38%(of the ways in which customers surveyed take in CBDs). Topicals were the next most commonly utilized method, at 19%; then: food or beverages, 18%; flower, 8%; pills/capsules, 7%; and vaping, 7%.
Â· Some 43%of consumers said they utilized less than 30 mg. a day; 22%reported using 50 mg. or more; and 12%used 100 mg. or more a day.
Â· Some 65%of customers surveyed stated CBD had actually favorably affected their quality of life. Only 2%explained an unfavorable effect.
Level of expense
Â· A lot of customers (59%) said they invested less than $50 a month on CBD.
Â· Some 46%of male consumers surveyed stated they used CBD at least as soon as a week, versus 36%of ladies in the survey population.
Â· Usually, males spent more for CBD than did females. Guys were most likely (21%) than females (12%) to spend more than $100 each month. Buyers ages 35 to 54 were the most likely (21%) of any group to invest more than $100 each month.
Â· CBD purchasers reported being usually delighted with the items they were able to purchase, depending on the guidelines in their geographical area; 71%agreed they were pleased with their purchases.
Â· When selecting which CBD product to purchase, cost and amount of CBD were the most essential factors to those surveyed. Benefit of location and service from staff were also crucial requirements.
Â· Some 51%of purchasers said they generally acquired familiar brands. About 29%stated they would be likely to purchase CBD in the next 6 months.
Where the Opportunities Lie
For CBD startups, the women’s market for might be one clever location to focus, thinking about that male survey respondents were far more likely (21%) than women (12%) to invest more than $100 per month.
Another smart relocation may be to market just items backed by clinical studies and clear, reliable information. The reasons here would be the importance customers place on reliable info, along with the stringent FDA restrictions versus promoting CBD for medical purposes.
Infusions as a technique for usage likewise appear to be of growing interest, while cigarette smoking is losing users due to social standards, specifically during the present COVID-19 crisis when numerous marijuana medical users are housebound.
Lastly, offered the anxiety throughout the crisis and the occurrence of word of mouth in spreading details about CBDs, companies might want to rely on such marketing channels as referral discount rates, commitment programs and high-production-value consumer testimonials, according to the New Frontier Data report.
In recent weeks, Aurora Marijuana ( NYSE: ACB) stock has seen brand-new life. It all started with the company releasing its third-quarter 2020 results on May 14, which revealed 18%revenue growth from the previous duration. A dedication to more improving its expenses likewise gave financiers a reason to be enthusiastic that profitability might not be simply a pipe dream.
Then, on May 20, the marijuana manufacturer also revealed it was acquiring Reliva, a cannabidiol (CBD) brand that would enable it to penetrate the U.S. market. As interesting a chance as that might seem at first glance, here’s why financiers shouldn’t put excessive stock in it.
It’s getting in an already crowded hemp market
Numerous headings promote Aurora’s current acquisition as the company entering the U.S. CBD market. While it’s technically true, it is worthy of an asterisk at the very least. All forms of CBD aren’t legal in the U.S. (federally), and Aurora can’t offer non-hemp items that contain more than 0.3%of tetrahydrocannabinol (THC). U.S. cannabis business that don’t operate nationally and rather run within states that allow medical or leisure pot aren’t limited to those restrictions. And until the U.S. federal government legislates medical or recreational marijuana, it’s a limitation Canadian cannabis business will face.
Image source: Getty Images.
The good news is that according to research companies BDS Analytics and Arcview Market Research, the overall CBD market in the U.S. is still anticipated to reach $20 billion by 2024, up from simply $1.9 billion in2018 The forecast didn’t break out the split between hemp and non-hemp items. And the problem is that the rosy outlook for CBD does not mean the chance is going to translate into substantial growth for Aurora.
That’s due to the fact that Aurora will not just be contending with other U.S. companies for market share, but with Canadian pot stocks that are likewise looking to take advantage of the chances in the hemp market.
Julie Lerner, who is CEO of the PanXchange where hemp is traded, validated in January that there was much more supply than demand for hemp. That’s not going to bode well for a company like Aurora, which is attempting to enhance on its margins and get closer to success.
Having access to thousands of locations doesn’t ensure development
In the news release revealing the acquisition of Reliva, there wasn’t a great deal of information on how huge of a player the company is in the hemp market. Although Aurora described Reliva as “a leader in the sale of hemp-derived CBD products in the United States,” there wasn’t anything to measure or justify that other than to say that its products were offered in more than 20,000 U.S. areas. According to analysts, Reliva’s sales over a 12- month duration ending in February amounted to $14 million in profits.
Hemp-derived CBD company Charlotte’s Web ( OTC: CWBHF), offers its products in less areas, and it has far more powerful sales.
A year back, the business tape-recorded sales of $217 million when its products were in more than 6,000 areas. The boost in locations over the past year hasn’t resulted in a rise in sales for Charlotte’s Web, and Aurora investors should not make the mistake of presuming more places suggest greater earnings.
The move doesn’t make Aurora a much better buy
Aurora anticipates Reliva to assist the Alberta-based pot producer inch closer to attaining a favorable adjusted revenues prior to income, taxes, depreciation, and amortization (EBITDA) figure. The acquisition may help play a small part in improving Aurora’s bottom line, however the company still has a lot of work to do in improving its financials.
The only certainty, it appears, is that the offer will result in more dilution for investors. The business anticipate the deal will close in June, and it will cost Aurora as much as $45 million in shares.
The acquisition is a modest one for Aurora that will assist contribute to its leading line, but that’s about it; Aurora stays a dangerous buy, and one quarter and one acquisition isn’t going to change that. The pot stock is still down more than 80%over the past 12 months, significantly even worse than the Horizons Cannabis Life Sciences ETF ( OTC: HMLSF), which has actually fallen by 60%.
David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Charlottes Web Holdings. The Motley Fool recommends Charlotte’s Web. The Motley Fool has a disclosure policy.”> David Jagielski has no position in any of the stocks mentioned. The Motley Fool owns shares of and advises Charlottes Web Holdings. The Motley Fool suggests Charlotte’s Web. The Motley Fool has a disclosure policy“>
So, things are pretty terrible right now. The world feels like a dumpster fire that spread to the bed of a garbage truck before setting the entire landfill ablaze. If you’re feeling overwhelmed or anxious or generally irritable, that’s perfectly natural, and there are plenty of tried-and-true methods you can use to lift your spirits: talk to a therapist, get in a good stretch, maybe turn on a soothing podcast. But what if there was something simpler, more immediate, and less expensive than that mail-order CBD subscription of yours? What if you could just throw on a pair of sunglasses and suddenly feel better, calmer, happier?
That’s the promised voodoo behind the first collection from Futuremood, a Bay Area eyewear brand that launched earlier this week. All of their sunglasses feature specially tinted lenses—using a new technology called Halochrome, developed by the German lens savants at Zeiss—that purportedly alter your mood by manipulating light and color.
There are four colors (or “auras,” as Futuremood likes to call them) to choose from, each one designed to elicit a specific feeling: green is for relaxation; red provides energy; yellow offers focus; blue refreshes your mind. The effect, Futuremood co-founder Michael Schaecher alleges, “is less subtle than CBD, but more subtle than caffeine.” The brand’s extremely extra website markets its wares, somewhat regrettably, as “wearable drugs.”
When Futuremood’s initial press release landed in my inbox, I rolled my eyes so hard that I altered my own mood. But then I looked around at the granola self-care habits I’ve developed, particularly as the days in isolation wear on: I meditate, I drink expensive vegan superfood shakes, I listen to corny Louise Hay affirmations on YouTube. Were Prozac sunglasses that different? If they could ease my existential angst—even by a fraction, even by placebo—then why not give ’em a shot? So I asked Futuremood to send me a few pairs.
What I received were three pairs with the red, blue, and yellow lenses. (Disappointingly, I didn’t get to test green—the “relax and soothe” aura—which I assume Futuremood expects to sell the most of right now.) Despite the techno-crunchy sales pitch—and the complimentary incense in the boxes—the glasses themselves don’t look gimmicky. They come in two frame styles: a classic, Moscot-esque keyhole shape and a chunkier clout goggles situation—all fashioned using top-notch Japanese acetate and gold-plated German hinges. The glasses also do shield your eyes from the sun: all of the lenses have full UV protection, along with anti-glare, anti-scratch, and water-resistant coatings. (Amusingly, the mood-shifting claims are powerful enough to warrant a note that warns not to wear them while driving—wouldn’t want to be too alert or calm on the road.)
I spent a few days testing all three pairs indoors and out—around 30 to 45 minutes at a time, which is how long Futuremood recommends before giving your eyes a break. To answer your question in as unsatisfying a way as possible, the glasses did…something. Did I feel the specific effects that Futuremood ascribed to each color—energy for red, focus for yellow? Not always, not exactly. But each of them yielded novel and, I guess, pleasing sensations. The blue lenses helped to balance out and color correct my apartment’s distinctly yellow, drab overhead lights I’ve been working under for two months now. The yellow pair made everything look a little bit like a Fincher movie: a mildly heightened sense of reality, with the contrast dialed up to 11.
The biggest trip of all were the red frames, which turned everything a searing crimson. It was legitimately disorienting at first, like waking up on an alien world or, as Schaecher puts it, “an underground Berlin club at three in the morning.” This certainly gave me a jolt at first, but more in a panicky my-edibles-just-kicked-in-hard way than a welcome double-shot-of-espresso one. Once I relaxed into the experience, though, it evened out to something akin to an amusing, low-grade lucid dream. I could see them maybe being fun to wear at, say, a music festival, if those ever actually happen again.
Whether or not the Futuremood glasses actively improved my energy is tough to say, but all three shades I tested absolutely put me at a slight remove from my everyday life—which felt nice for a little while. I did feel a soothing buzz during and after my wear tests. I think?
Dr. Ivan Schwab, the director of cornea services at the UC Davis Medical Center, isn’t arguing with the effects, though he doesn’t think it has anything to do with Halochrome™. “I think this falls more in the realm of psychology than it does in optics,” Dr. Schwab told me when I asked if there’s any scientific basis for the claims Futuremood makes about its lenses. The studies Futuremood cites, he said, are largely proprietary tests conducted by Zeiss. But in his view, it comes to how your brain—a product of nature and nurture—interprets color.
“The question I have is: Do other societies—completely different societies, like Amazonian tribes, for example—do they have the same psychology for colors as we do?” he says. He shrugged when I asked if they were some form of dangerous. As long as they had proper UV protection, there’s no harm. Besides to Dr. Schwab’s sense of style: “Those red ones, well, they might shock Elton John, for heaven’s sake.”
Are Futuremood’s sunglasses really combating the compounding anxieties that 2020 keeps hurtling our way? Probably not. But I do find myself reaching for them throughout the day, as I ramble around my apartment. I’ll take all the mood-altering I can get right now.
Futuremood Aurazone 100 sunglasses
Futuremood Aurabliss 5000 sunglasses
Futuremood Auraflow 100 sunglasses
Futuremood Auraboost 5000 sunglasses
Monthly, Fashionista editors try a lot * of appeal items And while not every formula we test is a winner, we’re constantly uncovering brand-new favorites. Here, we have actually assembled our most current hair, skin, fragrance, wellness and makeup discoveries— whether fresh-to-market drops or merely recent additions to our personal routines.
It was clear that group Fashionista was looking for a little convenience this month when it pertained to our charm regimens. We looked for products that would soothe our tension breakouts, muscle tension, frizz and minds. We also indulged in some fond memories (‘ sup, Juicy Tubes resurgence???), to make us feel a little better and possibly even a little confident, if only for a minute.
May’s top appeal and wellness picks? Lots of CBD for the inside and the out, heavenly-scented tension relievers, ritualistic charm tools, breakout-calming lotions, game-changing additions to our hair regimens and not one, however 2 various body oils that are weirdly suitable for warm-weather use.
Read on to see (and store!) them all.
I n case you missed out on last month’s choices, you can discover them here:
Please note: Periodically, we utilize affiliate links on our website. This in no way impacts our editorial decision-making.
A group led by researchers at Baylor College of Medication in partnership with Medterra CBD performed the first clinical research studies to evaluate the possible healing effects of cannabidiol (CBD) for arthritic discomfort in dogs, and the outcomes could blaze a trail to studying its effect in human beings. Scientist focused first on these animals because their condition closely mimics the attributes of human arthritis, the leading reason for discomfort and disability in the U.S. for which there is no effective treatment.
Published in the journal Pain, the study first revealed both in lab tests and mouse designs that CBD, a non-addictive product derived from hemp (marijuana), can substantially decrease the production of inflammatory molecules and immune cells associated with arthritis Subsequently, the study revealed that in canines detected with the condition, CBD treatment substantially improved quality of life as recorded by both owner and vet evaluations.
” CBD is quickly increasing in appeal due to its anecdotal health advantages for a variety of conditions, from reducing anxiety to assisting with movement conditions,” said matching author Dr. Matthew Halpert, research study professors in the Department of Pathology and Immunology at Baylor. “In 2019, Medterra CBD approached Baylor to perform independent clinical studies to figure out the biological abilities of several of its items.”
In the current research study, Halpert and his associates initially determined the impact of CBD on immune responses connected with arthritis, both in human and murine cells grown in the laboratory and in mouse models. Utilizing Medterra tinctures, they found that CBD treatment led to decreased production of both inflammatory molecules and immune cells connected to arthritis.
The researchers also determined that the effect was quicker and more reliable when CBD was delivered encapsulated in liposomes than when it was administered ‘naked.’ Liposomes are synthetically formed tiny spherical sacs that are used to provide drugs and other compounds into tissues at greater rates of absorption.
Halpert and colleagues next evaluated the effect of naked and liposome-encapsulated CBD on the lifestyle of pets detected with arthritis.
” We studied pet dogs because experimental evidence reveals that spontaneous models of arthritis, particularly in domesticated canine models, are more appropriate for assessing human arthritis discomfort treatments than other animal models. The biological characteristics of arthritis in dogs closely resemble those of the human condition,” Halpert stated.
Arthritis is a common condition in dogs. According to the American Kennel Club, it affects one out of 5 pets in the United States.
The 20 client-owned pets registered in the study were seen at Sunset Animal Healthcare Facility in Houston. The canine owners were arbitrarily offered with identical unidentified medication bottles that contained CBD, liposomal CBD, or a placebo.
After 4 weeks of day-to-day treatment, owners and vets reported on the condition of the dogs, whether they observed modifications in the animals’ level of pain, such as changes related to running or gait. The dogs’ cell blood count and blood signs of liver and kidney function likewise were assessed before and after the four weeks of treatment.
” We found encouraging results,” Halpert said. “9 of the 10 dogs on CBD revealed benefits, which remained for 2 weeks after the treatment stopped. We did not identify modifications in the blood markers we measured, suggesting that, under the conditions of our research study, the treatment appears to be safe.”.
Chris D. Verrico et al, A randomized, double-blind, placebo-controlled research study of daily cannabidiol for the treatment of canine osteoarthritis pain, Discomfort(2020).0000000000001896
Scientists find CBD improves arthritis signs in pets (2020, May 28).
recovered 29 May2020
from https://phys.org/news/2020-05- cbd-arthritis-symptoms-dogs. html.
This file is subject to copyright. Apart from any fair dealing for the function of private research study or research study, no.
part may be recreated without the written authorization. The content is attended to info purposes just.
Canadian cannabis kingpin Aurora Cannabis ( NYSE: ACB) closed its acquisition of Massachusetts-based cannabidiol (CBD) maker Reliva LLC last night in a $40 million offer(or more than two times that, if Reliva strikes specific financial turning points over the next couple of years).
That seems like great news, but financiers don’t appear persuaded that it is excellent news. Aurora Marijuana stock plunged more than 10%as soon as trading resumed today and hasn’t gained back much given that– down 8.5%as of 12: 15 p.m. EDT.
Image source: Getty Images.
Aurora interim CEO Michael Singer states the merger will “produce a market leading global cannabinoid platform that we believe can deliver robust earnings and profitable growth.” Financiers, however, appear more anxious about the cost Aurora paid for that development.
At $40 million, the purchase rate is about three times Reliva’s $135 million in estimated yearly sales– which would be a deal. If Aurora ends up paying the extra $45 million it has actually concurred to, for hitting “milestones,” nevertheless, the purchase rate will be something closer to 6 times sales– still a bargain relative to Aurora’s own stock valuation, however much slimmer.
Also of concern: Forty million now and perhaps $45 million later will take a huge portion out of the $175 million in cash on hand that Aurora had at last report. The company is bring $430 million worth of financial obligation (according to information from S&P Global Market Intelligence) and burning money at the rate of some $550 million every year (over the last 12 months).
So, was it a great idea to invest nearly half Aurora Cannabis’s money reserves to obtain a brand-new profits stream just 6%as big as the revenues that Aurora Cannabis was currently making? For today at least, investors think not.
Rich Smith has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”>
Austin Soldner and Michael Schaecher, the co-founders of the brand-new sunglasses brand name Futuremood, satisfied at the recently formed San Francisco research study and advancement lab produced by the high-end audio tech developer Bose.
The two were charged with working on Bose’s sunglasses wearable and bonded over a shared interest in tennis shoes and fashion. Over numerous discussions the two men realized there was a chance to utilize innovation to reword the sunglasses playbook and launch the first new brand name to the marketplace given that Oakley emerged.
There was also a chance to bring the products science and tech-forward techniques that sneaker companies have established to an industry that had not seen any real technical transformations in decades.
Enter Futuremood “Auras,” which the company costs as the very first glasses scientifically evaluated and proven to change your mood.
Using technology developed by the lens manufacturer Zeiss, Futuremood’s first glasses can be found in 4 colors– a relaxing green, a rejuvenating blue, a stimulating red and a focusing yellow. The company is introducing its eyeglasses in two styles, a boxy, chunky frame and a more conventional rounded frame.
Any mood-altering results are thanks to Zeiss’ halochrome lens technology, which the lens manufacturer has actually been working with– and publishing papers on– to suss out the science behind its claims that making use of filtered light can change the way folks feel.
There’s some preliminary research that the business has done, however the science is still mostly unproven (Zeiss carried out two studies at European universities).
Schaecher and Soldner are believers, and the two longtime tech officers see these lenses as a window into a wider world of product science experimentation and product advancement that they’re hoping to bring to market with Futuremood.
” If you think about sneakers and where Nike and Adidas got to where they are today, it was through development in item style and products and branding and marketing and all of that had actually been missing from the sunglasses area,” Schaecher stated.
The second marketing hire at Airbnb and the first marketing hire at the now-defunct Munchery, Schaecher understands a thing or two about branding. Meanwhile, Soldner, the creator of Playground.fm, and a former item designer at Jawbone, is the technical specialist and lead designer for all of Futuremood’s frames.
” We truly saw a chance to forge ahead in technical development and product innovation,” stated Schaecher. “We have a stockpile of stuff to forge ahead of what sunglasses are.”
Something sunglasses are is a really huge company. Consumers spent $145 billion on sunglasses in 2018, according to the market research firm, Grand View Research Study
If Futuremood can capture even a portion of that market with its unique spin on sunglasses, it’ll be in good shape.
As with any good direct to consumer item, Futuremood’s distinction starts with its packaging. Tapping in to the mood-altering “wearable drugs” aesthetic, the company’s product is packaged in boxes with the same bright hues as the sunglasses. Inside there’s a cloth to clean the glasses, a velvet pouch to hold them and a scented pack of incense matches and a vaguely tarot-esque card with details about the glasses and the experience they’re suggested to stimulate (there’s even a Spotify playlist to listen to).
In an email, Schaecher described the feeling as “not as subtle as CBD, however not as strong as a shot of tequila or glass of Rosé.
” Austin and I are truly into various ways of self care and taking minutes and … we believed there was an opportunity to bring pleasure and happiness,” with the packaging, Schaecher stated. “ We do not anticipate individuals to be shooting up Spotify playlists and incense matches every time they wear things.”
Futuremood has been mostly bootstrapped to date, and like everything else in the year of our Lord 2020, the company’s plans were pressed back by the coronavirus pandemic.
” Our lenses are made in Zeiss’ Italian factory and the glasses were made outside of Shenzhen,” stated Schaecher. “We quarantined the first order for two weeks. Zeiss was right because region of Italy that was getting struck hard. We’ve been postponing since then. It’s tough to put into words what it resembles to grind on something for eighteen months … and then need to delay launching.”
Even with the pandemic, though, the business moved ahead with the style for its second item, and that offers a tip for where Schaecher and Soldner want to go with their organisation.
The style aesthetic is also more in the luxury vein, which Schaecher teased was akin to something that would be more in the house in a Cartier showroom instead of a direct to customer brand name’s digital storefront.
Today, the company is going direct to customers through its website, but it’s looking at the capacity for some retail partnerships and field marketing when the country opens back up for company.
As for the mood-altering impacts and whether “wearable drug” can win market share, Schaecher is quite positive.
Boing welcomes Genuine Checked CBD as a sponsor!
Real Evaluated CBD is known for efforts in bringing information about the CBD items for not only recognized brands, but the budding brand names in the specific niche. Thanks to the laws in the United States that permit legal production of CBD products for health and research study, there are some premier products on the market, but it’s important to know what you are going shopping for to guarantee the best purchase.
We at Real Checked CBD run all the products through laboratory tests and present whatever in black and white for our readers. Today, we review Charlotte’s Web and its CBD items that consist of balms, creams, tincture, edibles, and pills.
Here is a review of all the nine items of Charlotte’s Web that we tested.
This hemp-infused balm by Charlotte’s web features 150 mg of botanical blend hemp extract. It has a calming scent, and we found no traces of pesticides and solvents in the mix. Furthermore, it contains all the goodness of CBD at 107.2 mg per pack. It likewise contains THC at 4.69 mg and CBC at 4.48 mg per plan. Our test results show that the total CBD levels were lower than those declared on the label.
This Dog hemp-infused balm is for adult pets with 450 mg of hemp extract. Our test results show the CBD levels are half the amount of what the label claims. It does consist of a decent CBD quantity still together with other advantageous cannabinoids. The CBC and THC levels are at 8.67 mg and 5.53 mg per plan; whereas, CBD levels are at 224.28 mg per package without any indication of pesticides or solvents.
This hemp-infused skin cream comes with 750 mg of hemp extract. It does contain some CBD goodness, but our test results suggest these levels to be lower than the label’s claims.74 of CBD loaded in this product.
Wow, this CBD isolate tincture by Charlotte’s web is one of our favorites. It provides 20 mg of CBD per drop, and our test results show that this tincture includes more CBD than the label claims, which is an excellent thing as it increases the effectiveness of this product. The CBD levels are a massive782
This Web Hemp extract tincture is an excellent CBD product that is real to its label claims. We would state a fantastic job! It uses 12 mg of pure CBD extract that provides other beneficial cannabinoids present in natural hemp extract used in this product. It consists of THC, CBC, and CBG at 17.87 mg, 17.65 mg, and 3.11 mg per package, respectively. The overall quantity of CBD per plan is 533.8 mg, without any trace of pesticides or solvents.
Our laboratory tests found an acceptable range of CBD per cylinder at below 25%. It appears to be full-spectrum CBD and includes CBC and THC in the mix, which makes it spot on with its entire hemp extract claim. The CBD, THC, and CBC quantities are at449
Boing happily welcomes EST as a sponsor. The Torch L1 by EST Gear is the world’s most versatile flashlight. It features a special L-shaped style so you can use it hands totally free as a headlamp or stand-it up with it’s ultra-handy, flat, magnetic bottom. Stick it, clip it, carry it or use it. This […]
https://www.youtube.com/watch?v=-sQGbtjBMX4 Boing is proudly sponsored by Personal privacy Safe! Pre-order now to take benefit of early-bird pricing and get discounts on other privacy-respecting services and open hardware. Cutting […]
Boing is proudly sponsored by Sugar and Kush! Click to Leap to an Area: Unhealthy CBD products Uncontrolled CBD Industry Pure Unflavored CBD Oil Best Carrier Oils for Bioavailability Laura Brenner & Sugar & Kush CBD Conclusion Cannabidiol, or CBD, is one of the lots of cannabinoids found in the cannabis plant. Unlike the more […]
” Live as if you were to pass away tomorrow. Find out as if you were to live forever”– Mahatma Gandhi Of all the skills you feel like you need to probably understand, yet likely do not, coding might be among the most intimidating. From the different programs languages to the variety of platforms to the sheer pain […]
Despite the fact that it feels like Amazon is a particular retail juggernaut crushing everyone else, you might be shocked to discover that half of Amazon’s $280 billion in earnings last year originated from third-party sellers. According to numbers put together by JungleScout, 86 percent of Amazon’s Fulfilled by Amazon (FBA) sellers were profitable in 2015, more than […]
Amidst all the fatal severe issue and fallout from our international fight versus COVID-19, you’ve likely been forced to face more than a few moments that you never ever anticipated to deal with. And you likely never felt sillier during this scary time than when you were racing all over town hoping desperately that some store had […]
Japanese business, Hiro International, has actually derived cannabidiol (CBD) oil from orange peels. Free from tetrahydrocannabinol (THC), the psychedelic active ingredient in marijuana, Ryousuke Koseki, a company spokesperson, stated that the product might make CBD offered in locations with stringent guidelines against THC and cannabis-derived products.
Hiro International was founded in 1984 and initially imported fruits and fruit juice. It soon found that orange peels imported from the United States consisted of CBD structurally identical to that found in hemp.
The business later on found it was able to boil down the CBD found in orange peels into oil for numerous applications.
” Orange-derived CBD Oil has the very same ingredients as hemp CBD, similar results, and in addition, zero danger in terms of THC intake and legality.
Previously, the business has actually not evaluated the effectiveness of orange peel CBD versus CBD stemmed from hemp. Although they said they might check out it soon, whether their version of CBD is effective is thus still open for dispute.
Early research studies have found that other alternatives for CBD are just as efficient as more efficient than regular CBD. A research study performed by Peak Health on its hops-derived CBD item, ImmunAG, discovered that it was more effective at minimizing calcification in the heart than cannabis-derived CBD at ‘every concentration’.
Nevertheless, the release of Hiro’s orange peel hemp products is excellent news for those wishing to use CBD in Japan, where THC- even in trace amounts- is extremely illegal. Given that 45% of the 250 best-selling CBD items are understood to include THC, and that using CBD items may trigger users to stop working drug tests, an item unconditionally free from THC is considered as a safe option.
Currently, it appears that these items are only available in Japan. The company has not commented when they will be offered worldwide.
Releases Mobile Screening Website …
Let’s Get FL Back in Biz!!!
5/27/202012: 30 AM PT.
Flo Rida‘s partnering with his personal doctor– and dropping his own money– to get COVID-19 testing ramped up at Florida companies attempting to reopen safely.
The rap artist– together with his doc and business partner, Dr. George Tabi— have actually launched a $1.5 million healthcare venture together called the Asktabs Mobile Health Center … with the objective of getting healthy people back to deal with the heels of the state reopening its economy.
That requires a great deal of coronavirus screening, and Flo’s mobile website boasts the ability to check up to 1,500 clients each day with a staff of approximately 14 individuals.
The Asktabs mobile center had its preliminary of tests last week for The Metro Wrapz business in Miami, where we’re informed 30 staff members got evaluated.
Flo Rida’s mobile website is offered for anyone, but we’re informed the main focus is supplying screening for organisations so employees can get their tasks back as quickly and securely as possible. The rap artist and his medical professional wish to take a trip to other cities around the Sunlight State, also.
This isn’t the duo’s very first healthcare project either– they formerly released an immune-boosting day-to-day vitamin gummy that’s CBD instilled, called Jet Setter. As you can see, they’re repurposing their vitamin van to carry screening products.
Now, that’s being resourceful.
“Cannabis Treats COVID-19” Rallied Weed Stocks. Cannabis Could Aid Pandemic—If Someone Pays To Find Out.
Already down when the coronavirus pandemic kicked all markets, a few cannabis stocks enjoyed rallies Friday — gains connected, it would seem, to the coronavirus pandemic.
Colorado’s CBD giant Charlotte’s Web, named for pediatric cannabis patient Charlotte Figi, who died last month of complications from the coronavirus, was up 24 percent on the Toronto Stock Exchange. But the big gain was on NASDAQ, where shares in Canadian firm Sundial spiked 50 percent—a jump, to $0.83 a share, that’s nothing close to wiping out last year’s losses, but nonetheless a very big rally in context.
And a rally “vaguely” timed, as MarketWatch reporter Max Cherney observed, with the New York Post’s publication Thursday of its take on the big story that had gone viral on Facebook earlier that month, and was later flagged as fake news: the claim, first made in a preclinical paper published in April, by Canadian scientists that certain high CBD strains of “cannabis could prevent and treat coronavirus.”
Cannabis and COVID together strikes a nerve, already: since the beginning of the pandemic, unscrupulous cannabis companies have been claiming, without any data, that their products might manage COVID symptoms or even act as a preventative. But this wasn’t that, as researchers at the University of Lethbridge explained in interviews with the Calgary Herald and CTV, recycled by the Post.
In experiments with 3D human cell cultures mimicking various diseases, certain high CBD cannabis strains—developed by the researchers labs, in no relation to the cannabis available in legal and recreational markets in Canada or the US—demonstrated abilities to shut down coronavirus’s favorite “pathway: a receptor called ACE2.
Rife in lung cells but also present in the mouth and gut, ACE2 regulates the virus’s ability to enter cells and replicate. One of the Lethbridge CBD strains downregulated the ACE2 receptor in certain 3D cells by as much as 73 percent, according to Lethbridge biological scientist and study lead author Igor Kovalchuk. This is a reason why the ACE2 receptor, and turning it off, is the target of pharmaceutical interventions like experimental novel coronavirus vaccines—and this is why a consumer product that contains one of the Lethbridge-grown cannabis strains might be a useful supplemental therapy for COVID-19 patients. Perhaps in a mouthwash, the preclinical paper suggested.
None of this means cannabis is a COVID-19 cure, or a COVID-19 prevention—just, maybe, a COVID-19 treatment. That didn’t stop certain media outlets, including one weed publication called out by name by The Poynter Institute’s Politifact in a May 18 item, from running items “overstating” the Lethbridge scientists’ findings, as Kovalcuk himself admitted. But the Post got it right.
“It reduces the possibility to get infected. I never said it would prevent or block it entirely,” he said in a telephone interview over the weekend.
“It is a possible treatment,” he added. ‘A treatment is not a cure. When [news reports] say it treats COVID, or can potentially treat COVID, they are absolutely right.”
For Kovalchuk’s research team, the coronavirus pandemic struck at an auspicious time. Kovalchuk runs a company called Pathway Rx. Pathway is a Sundial subsidiary—a fact not mentioned in the Post—and earlier this year, after the company’s fortunes had plummeted from summertime trading of $12 a share to this winter’s sub-$1 nadir, his team’s research was close to getting shut down for lack of money.
When COVID appeared, “I thought, well, it’s a virus, it’s inflammation, there must be something cannabis does,” Kovalchuk recalled. So his team dived back into the models. And since COVID-19 attacks the ACE2 receptor, a receptor his strains seem to block, “the rest is history.”
As for the temporary market gains, “I don’t really care,” Kovalchuk insisted. “I want this to be brought to people. And that can only be done once a clinical trial is done.”
The trick now is to convince an investor—be it a cannabis company or anyone else—to pay for study that involves humans. This will require even more money.
For around $700,000 US, Kovalchuk believes he could enroll several hundred human volunteers — COVID-19 patients willing to supplement their doctor-prescribed regimen with a Pathway Rx cannabis product, to see if their recoveries were quicker or their symptoms less severe than a control group’s. If hospitalization stays, length of illness, and other indicators among the experimental group dropped by 20 percent compared to control, more study and a larger cohort would be required. If it were 50 percent—then maybe we’d have an accepted additional therapy.
For now, the main takeaway is that “cannabis,” meaning the stash in your jar, or the stash available at the dispensary, or the CBD oil flogged online, isn’t going to do anything. Pressed for details about terpene notes or full cannabinoind spectrum information about his special strains, Kovalchuk stayed mum. But he did emphasize that it’s very likely the full spectrum of terpenes and cannabinoids, not just the high-CBD/low-THC ratio, that’s finding success inhibiting the ACE2 receptor favored by the coronavirus.
“It’s very important that it’s not just generic CBD,” he added. “You just can’t go anywhere and get CBD [that will work on COVID-19]. That’s why we’re afraid of people just rushing out to start buying it.”
Which, apparently, people have done—and not just CBD, but CBD stocks, too.
So you think the cannabis sector has seen its worst? That there’s no coming back? Well, here’s a twist: The COVID-19 pandemic might have dragged down most sectors, but it is lifting up marijuana stocks for sure. Cannabis sales skyrocketed in April amid the pandemic, pushing companies’ revenues higher. In fact, most marijuana businesses reported good revenue numbers this quarter. But one, in particular, seems to have risen from the dead.
A phoenix from the ashes
Edmonton, Alberta-based Aurora Cannabis (NYSE:ACB) saw strong demand after Canada legalized recreational marijuana in 2018. The company ramped up its production facilities, paying little attention to its rising debt. External factors including black-market sales and a slow rollout of stores post-legalization made it harder for the company to make a profit; ultimately, investors lost trust, and the stock kept sinking below $1 — to the point that it was at risk of being delisted from the New York Stock Exchange.
Image Source: Getty Images.
In May, however, Aurora seems to have risen from the dead. To save its stock and strengthen its cash position, it consolidated its shares in a 1-for-12 reverse stock split. Surprisingly, its third-quarter results were a hit. The company recorded year-over-year revenue growth of 16%, to 75.5 million Canadian dollars. It also reported sequential quarterly sales growth of 35%.
Its Q3 consumer cannabis revenue was up 24% sequentially to CA$41.5 million; that included its Daily Special brand, launched in February, and a few of the cannabis 2.0 products, launched in December. Medical cannabis revenue also increased by 13.5% sequentially. Management said they didn’t see much impact from Covid-19 in the third quarter, but they do expect it in Q4.
Despite a good quarter, it’s smart to be skeptical. Q3 results can’t hide the fact that despite rising revenues, Aurora reported negative EBITDA (earnings before interest, taxes, depreciation, and amortization) of CA$50.8 million in Q3. Selling, general, and administrative (SG&A) expenses in the third quarter came in at CA$75 million. Management assured investors that Aurora is working to reduce SG&A and hit positive EBITDA by Q1 2021, but analysts remain skeptical.
Making it more exciting: A strategic acquisition in the U.S. CBD market
Aurora Cannabis is marking its entry into the U.S. cannabidiol (CBD) market with the acquisition of hemp-derived CBD company Reliva. The deal will leave Reliva’s shareholders with $40 million worth of Aurora’s shares, and that number could rise to $45 million over the next two years if Reliva achieves certain financial targets. The transaction will close by June.
What worries me is that Aurora might be reliving its past mistakes. Not even a month ago, it was drowning in debt, and now it’s making acquisitions? Don’t get me wrong; the U.S. CBD market is a rising star. It’s just that these products still face doubts from the U.S. Food and Drug Administration (FDA), which seems hesitant about the use and marketing of CBD products in the U.S.
That said, striking a deal with a company that has no debt and a strong market position in the U.S. — Reliva boasts 20,000 retail stores — could prove to be a wise move. Reliva also generated positive EBITDA over the past 12 months, ending in March. Reliva’s U.S. management team will be part of Aurora, and that might just help the latter company, given that its current leadership team has proven questionable.
Recently, Canopy Growth (NYSE:CGC) also announced the launch of its next batch of cannabis 2.0 products — cannabis-infused beverages, chocolates, and vapes. Canopy Growth, along with its partner, Constellation Brands (NYSE:STZ), expects to capture a new range of customers with its innovative products.
Achieving profitability is what matters
Shares of Aurora and Canopy are up 106% and 16%, respectively, so far in May, while the SPDR S&P 500 ETF (NYSEMKT:SPY) has declined by 4.1%.
The stock volatility could drag on with the market uncertainty around the pandemic. What matters to cannabis investors is whether Aurora can sustain its promises, manage to reduce expenses, and hit profitability within the stated time frame. Aurora’s entry into the U.S. CBD space and its innovative cannabis 2.0 products present a good opportunity for the company to recover in 2020.
Sushree Mohanty has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Constellation Brands. The Motley Fool has a disclosure policy.”>
On May 20, Charlotte’s Web, the Colorado-based CBD giant and probably among the biggest names in legal cannabis, revealed that the company was granted its 2nd federal patent on a marijuana plant.
Unlike the company’s 2018 plant patent on a Farm Bill-compliant high-CBD hemp cultivar– which was the first hemp pressure to get federal intellectual property protection– US Patent No. 10,653,085 is an utility patent
This implies, after pleasing a more extensive process, consisting of dropping off countless seeds at an official United States depository, Charlotte’s Web now declares as its intellectual property both the cultivar of hemp the company calls CW1AS1 in addition to “techniques” of plant production and cannabinoid extraction.
Okay! Why patent a hemp pressure– why patent 2?
To the last question, no. And as for what this means, for typical individuals and marijuana customers, extremely little. For patent lawyers or rivals of Charlotte’s Web in the CBD market, it hints a little more, but just a little.
A minimum of for now, cannabis patents like this one aren’t truly planned to safeguard copyright in court– which is where a patent has its most practical value.
No, this patent is probably indicated for the market. I have a patent” might be the difference in between signing a check, or not.
Patents “create interest in the business, and are something financiers would look at,” stated Jonathan Hyman, a patent attorney and partner at the Los Angeles workplace of Knobbe Martens.
Whether Charlotte’s Web would enforce the patent, and how, “remains to be seen,” he added.
Company authorities were not available to go over the matter. In a declaration offered by Sylvia Tawse, the company’s director of interactions, CEO Deanie Elsner said Charlotte’ Web “will continue to pursue patent security for distinct and novel hemp genes developed by our horticulture division.” Whether that implied there are any pretenders the business plans to take legal action against, she did not state.
Though cannabis-related patent applications have been a thing because well prior to legalization and have actually tripled considering that 2015, as IP Watchdog noted, the mere expression “cannabis patent” can still be setting off in cannabis circles. Patent talk can typically cause galaxy-brain thinking like the “Monsanto is supporting legalization in order to steal cannabis” or the “Philip Morris is purchasing up land in Humboldt County” conspiracy theories.
In the case of Charlotte’s Web, the company’s currently locked up what’s probably its most valuable asset: its name. Charlotte’s Web is named for Charlotte Figi, the sufferer of childhood epilepsy who enjoyed remedy for her symptoms after taking an extract of high-CBD cannabis grown by the Stanley brothers (and who passed away earlier this month after contracting COVID-19).
The world familiarized Charlotte Figi and the Stanley siblings, seven photogenic Coloradans whose given names all begin with J, after they were prominently featured in a 2014 CNN unique hosted by Sanjay Gupta. A really popular kids’s book and a very famous and identifiable name, the business was sure lock down the name “Charlotte’s Web” with a hallmark– one the company is currently defending in federal court, after a rival business attempted market CBD products called Charlotte’s Web.
That’s what patents are for in terms of the law. However markets are another matter– and it’s worth observing that the business went public after securing its very first patent.
Like practically all publicly traded companies in the cannabis sector, Charlotte’s Web is stuck in high-loss doldrums after striking early peaks.
For the past week, shares in Charlotte’s Web have been trading in the $7 to $9 range in the Toronto Stock Exchange.
In spite of being offered in more than 11,000 stores, the business still lost $1.7 million in 2020— a struck smaller sized than other companies in the cannabis sector, but still in the red.
Patenting hemp genetics and the processes to achieve them won’t be enough to rescue the remainder of the company’s declined. If Charlotte’s Web desires to be a global CBD brand, with item in supermarkets and benefit stores all over the world– and why wouldn’t it?– this indicates something.
” Having this patent, that they can wave around and say, ‘Hey, we’ve got protection on it, and it’s the best range [of CBD rich hemp] that you’re going to get,'” said Andrew Merickel, who holds a Phd in neuroscience and is likewise an attorney and partner at the San Francisco office of Knobbe Martens. “That’s quite important.”
How valuable? That’s all approximately the logic of the marketplace.
Not long ago, previously acquisition-happy marijuana companies put the brakes on costs. Collectively, they lost cash a lot more often than they made it– so grabbing brand-new assets to develop scale ended up being a less hot concept than it had been a couple of years back.
That was then, and this is now. Recently’s huge cannabis business news was a throwback to the excellent old days of 2018 approximately, with Aurora Cannabis( NYSE: ACB) finalizing on the dotted line for a buyout. Another essential pot market event transpiring recently came when a major dispensary operator reporting its latest set of revenues. Here’s more on both advancements.
Image source: Getty Images.
Aurora purchases Reliva
Canada-based Aurora is reaching across the border for that acquisition. It announced it has consented to buy U.S. hemp-derived cannabidiol (CBD) products maker Reliva in a deal for approximately $40 million in Aurora typical stock, plus approximately $45 million over the next two years in cash, stock, or a mix of the 2 if Reliva satisfies particular financial objectives.
Aurora stated it anticipates Reliva to be “right away accretive” in terms of every marijuana company’s preferred functional metric– adjusted EBITDA. This would help Aurora, as it’s needed by financial obligation covenants to be adjusted EBITDA-profitable general in Q1 of next year.
Aurora didn’t state whether Reliva pays on the bottom line; I’m assuming it’s not if adjusted EBITDA is pointed out in place of net profit/loss. Its annual revenue is $13 million to $14 million, according to a report in MarketWatch; for scale, Aurora’s leading line in 2019 hit practically $248 million Canadian ($177 million).
This buy is rather unexpected, considered that Aurora has been in retreat mode since late last year. It suspended building and construction and expansion activities at two of its facilities, hung a “for sale” sign on one of its greenhouses, and in the wake of the SARS-CoV-2 coronavirus furloughed around 500 of its workers.
While investors can be guardedly favorable about some recent news with Aurora, such as its newest set of quarterly outcomes, I do not think they should rejoice here.
Yes, CBD products are stylish among particular customers just now. They aren’t the huge and fast-growing cash spinner that would make an acquisition like this have a significant effect.
The company’s balance sheet isn’t particularly strong, and it tends to release and spend its own stock a bit too much for comfort, in my view. The Reliva acquisition does not move the needle on my typically bearish position on Aurora– regardless of some encouraging numbers in its Q3, it was well at a loss for the quarter. It continues to have a hard time with many of the same troubles affecting its Canadian marijuana peers
Curaleaf’s mixed Q1
The marijuana producer and retailer didn’t hit the typical expert estimate for earnings, but it wasn’t too far away from it. Plus that line product increased by almost 30%quarter over quarter to nearly $965 million. Net loss, meanwhile, was narrower than anticipated and a substantial enhancement over the preceding quarter’s result.
Curaleaf’s retail focus appears to be serving it well; dispensary openings and acquisitions were the moves that helped lift that top-line figure. And in many states– although not necessarily the company’s house of Massachusetts, at least initially– cannabis stores have actually been categorized as “vital” services allowed to run through the coronavirus pandemic. This should assist keep the business afloat in the coming months.
It’s sounding a bullish note about the rest of 2020, predicting that both profits and the bottom line will continue to improve. On the other hand, the business appears to have sufficient money for now, so possibly it will not be tapping the financial obligation or equity markets for new funding soon, as it has in the recent past.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.”> Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy“>
On a normal Saturday, at 4: 30 am, Stone, Colorado-based competitive ultramarathoner Flavie Dokken takes 5mg of Wana Recreational Tarts, puts on her running shoes, and navigates a five-hour run. But Dokken is not your normal stoner, she uses cannabis as part of her exercise regular and she is sponsored by Wana Brands, a cannabis company that produces cannabis-infused items. Dokken told Vice that the gummies help her tune into her breathing. Dokken uses THC (tetrahydrocannabinol, the psychedelic aspect of marijuana) during training, she stops using it a week prior to race day due to the fact that of drug testing.
” Active lifestyle” may not be a set of words commonly connected with marijuana usage. Marijuana business are attempting to alter that by sponsoring professional athletes and athletic teams, getting them to publish pictures of products on their Instagram grids or put brand sticker labels on their athletic equipment, in order to acquire visibility with the athletes’ fans.
Brands like Nike, Saucony, and New Balance, associated with the running market, do not enable their athletes to be connected with cannabis. That doesn’t imply they never ever take part. Dokken stated she knows of a handful who do. Not just are they secretive about their usage, however they also avoid associating with her for worry of regret by association. She said that these professional athletes, “will not follow me on Instagram,” however she also states that when she wears her Wana equipment on the tracks in Colorado, “individuals give me a high-five, which is amazing.”
Even as huge brands don’t wish to talk about marijuana use, it is progressively officially approved for competitive professional and amateur professional athletes: In 2018, the World Anti-Doping Firm (WADA) Code removed CBD from their list of prohibited compounds, and allows a professional athlete to have THC in their system during a random out-of-competition drug test. However THC is still a prohibited substance for post-race or in-competition drug tests; this all ways athletes are fine to use cannabis throughout the off-season and even throughout training, however can not take on the drug in their system.
In 2018, Canada legalized marijuana with the Marijuana Act, which prohibits professional athletes from being sponsored by cannabis business. Canadian Mixed Martial Arts fighter Elias Theodorou is trying to alter that. He uses cannabis for discomfort management for bilateral neuropathy in his upper extremities (persistent discomfort in his wrists, elbows, upper neck, and spinal column). “Physician prescribed marijuana is the very best medical alternative to handle my discomfort,” he told VICE. “Conventional, first-line medications like pain medication, opioids, and NSAIDs have all had detrimental side-effects to my body as both a client and professional athlete.”
Theodorou, who has been sponsored by Pert Plus, Mattel, and Coors Light, discussed, “This fight is not just about working with marijuana business, however also the need to tear down the barriers and negative perception other business might have with cannabis.”
Mendi, a CBD start-up company, has “professional athlete ambassadors” who assist promote their products, consisting of soccer gamer and Women’s World Cup winner Megan Rapinoe, and her sweetheart, WNBA gamer Sue Bird. The athlete ambassadors receive Mendi items to promote on their social channels and attend Mendi events. The business was established by Rapinoe’s twin sibling, Rachael, who is also a previous professional soccer gamer. Although CBD is banned in the WNBA, Bird uses it in her off-season. She informed New York City Magazine, “It’s terrific for recovery and it relaxes me. I generally take it during the night so I can sleep, which assists with healing, and have actually had fantastic outcomes.”
While making use of marijuana may appear diametrically opposed to what a professional athlete worths– inactiveness versus action– calm, relaxation, and rest are important to athletes’ general success and wellness. However professional athletes do not even restrict use to off-hours in our modern-day times: In 2019, The University of Colorado Stone released a study on over 600 runners with legalized marijuana that found 80 percent of cannabis users mixed workouts with marijuana use. Cannabis is not a performance-enhancing drug, Dr. Rosemary Mazanet, Chief Scientific Officer of Columbia Care, claimed to VICE it can help diminish efficiency stress and anxiety. “You’re able to be more in the minute and have more enjoyable, to be more limber, to be more versatile,” stated Manazet.
Pulmonologist Vandana A. Patel stressed to VICE via email that cigarette smoking cannabis can adversely impact an athlete’s efficiency. “Inhaling cannabis can trigger structural lung injuries, like building air pockets in the lung which can burst under increased physical stress.” Due to the fact that of this, numerous professional athletes, like Dokken, stick to edibles.
The owners of the Oregon-based dispensary Tokyo Starfish all previously worked in the snowboarding market before they transitioned into opening a dispensary. Tokyo Starfish-sponsored expert snowboarder, Max Warbington described that the dispensary concentrates on the lifestyle element of snowboarding instead of the performance aspect.
Tokyo Starfish-sponsored snowboarder Nora Beck told VICE that she utilizes cannabis throughout snowboarding when she requires to relax. She explains, “It’s like you’re on hyperdrive and you simply need to turn the volume down a bit.”
” Tokyo Starfish is really purchased snowboarding and they comprehend that I’m out there doing my task as a professional snowboarder and just the fact that I have the Tokyo sticker that’s like a total reward for them,” Warbington said. As a pro snowboarder sponsored by Tokyo Starfish, Warbington sends the business videos and images throughout the winter season. He also uses their T-shirts and hoodies and markets them to snowboarding fans on his social networks.
When asked whether he feels like there’s a stigma as an athlete sponsored by a cannabis business, he replied, “I think they’re probably constantly will be [a stigma] just the same as there’s a stigma with alcohol since it’s a compound that individuals abuse.”
In a phone interview with VICE, Warbington stated he is especially conscious of his image. “I definitely don’t want to push it [cannabis] on the youth and that’s why I constantly like to preach that.” He does not permit Tokyo Starfish to publish images on their social media of him smoking pot, though Warbington in some cases posts an image of a joint in his personal Instagram stories. He said, “I always second-guess it each time because of my influence.”
Brands like Tokyo Starfish and Wana are attempting to fight negative associations with marijuana. They desire the general public to affiliate the recreational drug with an active lifestyle. Warbington said it’s really important to him that individuals know he and his Tokyo Starfish teammates do not personify the “lazy stoner” stereotype. Vice versa. “We’re out here smoking weed,” he stated. “We’re the very first person up [on the slopes in the morning] and the last one to leave the mountain.”
Cosmetics brand taps into two major trends expected to continue after Covid-19
e.l.f.’s Chipotle-inspired makeup kit sold out in 4 minutes (though supply was limited).
A new Chipotle-inspired prom makeup kit by e.l.f. Cosmetics is the result of an unusual but clever mashup with the fast-casual chain, and sold out in mere minutes Thursday, CMO Kory Marchisotto told Adweek.
The cosmetics and skincare company also launched a line of full-spectrum CBD skincare products this week to appeal to shoppers’ heightened desire for skincare and wellness products during the pandemic, she added.
The collaboration and the new offerings are the latest examples of how brands are coming up with inventive ways to boost business in a difficult time.
“E.l.f. and Chipotle go together because our values align,” said Marchisotto, adding that such efforts also fulfill the company’s desire to put a smile on people’s faces during a difficult time.
The mission of e.l.f. is to make beauty accessible to every eye, lip and face, while Chipotle’s aim is to make better food accessible to everyone, she noted.
“Like Chipotle’s commitment to responsibly sourced food, e.l.f. prides itself on 100% vegan products, and the parallels certainly don’t end there. Both brands are quick-thinking, agile disruptors who can move fast on ideas that resonate with the Gen Z audience,” said Tressie Lieberman, vp of digital and off-premise marketing at Chipotle.
While brand mashups are not new, they will likely gain traction as consumers seek unique products and experiences that stand out from the crowd.
The offering is part of a broader collaboration between the cosmetics brand and Chipotle, which is hosting a virtual prom afterparty Friday evening following Teen Vogue’s virtual prom event.
The kit includes a silver pouch that resembles a wrapped burrito, while the makeup includes a primer-infused brush as a stand-in for guac, a lip exfoliator called Brown Sugar in lieu of brown rice, and a putty primer matte in place of sour cream.
In addition to the partnership, e.l.f. is recalibrating its product lineup to include more skincare and health and wellness products, as demand for those items has spiked during the pandemic.
In particular, the company launched a line of full-spectrum CBD products, which have trace amounts of THC, including a facial oil, an eye cream, a body cream and a moisturizer.
The CBD line caters to consumers’ need for a moment of calm and self-care, especially in this anxiety-ridden moment for the world, Marchisotto said. “What we see now is a blurring between wellness and beauty,” she said.
It’s also part of e.l.f.’s culture of testing and learning. “We have a high risk tolerance,” she said. It comes from the original founders’ desire to sell a premium product for $1 over the internet some 16 years ago, and against the odds, succeeding. “They made the impossible possible,” Marchisotto said.
Like with TikTok, which e.l.f. has had a presence on since the platform’s early days, the cosmetics company doesn’t overthink—it tests and repeats what’s successful, Marchisotto explained.
For example, the beauty brand issued a hashtag challenge featuring an original song on TikTok to test the platform and measure customer engagement, which as of May 10 resulted in the creation of 3.5 million videos and generated 5.2 billion views.
In another example, the full-spectrum CBD line builds on the successful introduction of cannabis sativa-infused products late last year such as Happy Hydration Cream, Calm Balm lip balm and Puff Puff Primer.
Being first to market with innovative products is one of the things e.l.f. prides itself on, Marchisotto said. “One of things e.l.f. does brilliantly is we build on demands we hear, sentiment we hear.”
Editor’s note: This article was updated to reflect the latest numbers for e.l.f.’s TikTok hashtag challenge, which resulted in the creation of 3.5 million videos and 5.2 billion views.
Graphic Designer: Zac Jacobson
Location: United States
Job Type: Produced
Customer: Coastal Clouds CBD
Product Introduce Location: Global
Packaging Contents: Oil, CBD
Product Packaging Substrate/ Products: Glass bottle
Printing Process: Digital printing, foil marking
Influenced by the naturally calming impacts of ocean waves & gently rolling clouds, the CBD brand is offered to assist individuals with discomfort, stress and anxiety & tension. We created product packaging reflecting that goal.
The labels are quite little on the casts, but we were still able to manage some foil on the logo to enable the product packaging to feel more premium.
The enactment of the 2018 Agricultural Improvement Act (the 2018 Farm Bill) and the legalization of hemp and hemp derivatives, including hemp-derived cannabidiol (CBD), has led to a massive CBD craze. Nevertheless, the FDA’s position against the sale and marketing of CBD-infused foods and dietary supplements has resulted in an insurgence of products infused with lesser-known cannabinoids.
In light of this recent shift in the industry, this piece explores how these “novel” cannabinoids might be regulated as foods or dietary supplements under federal law, using the current CBD regulatory framework as a starting point.
Before diving into the regulatory framework of these lesser-known cannabinoids, it is important to understand what cannabinoids are.
Cannabinoids are chemical compounds found in the cannabis plant. The most notable cannabinoids are tetrahydrocannabinol (THC), which is the most psychoactive compound in cannabis, and CBD, THC’s nonpsychoactive cousin. Yet, there are over 100 compounds in the cannabis plant that affect the human body in their own unique way. Two cannabinoids have begun getting a lot of attention are cannabigerol (CBG) and cannabinol (CBN).
CBG is the “mother” of all cannabinoids; it helps synthesize other cannabinoids, primarily THC and CBD. Though scientific research remains sparse, CBG has been found to act on specific physiological systems and problems, such as treating glaucoma, decreasing inflammation, and offering antibacterial properties.
While CBG is the precursor of cannabinoids, CBN is the product of a degradation of other cannabinoids. Specifically, CBN comes from the oxidation and decomposition of THC. As for CBG, current research on the effects of CBN is limited; yet, CBN is showing promise as a potent antibacterial agent, an appetite stimulant and as a possible sedative.
CBG and CBN, like CBD, fall under the federal definition of hemp, which means these cannabinoids can be lawfully cultivated so long as they contain no more than 0.3% THC on a dry-weight basis. Because CBG is formed prior to THC in the hemp plant, many in the industry believe cultivating CBG strains will help them circumvent the stringent preharvest “total THC” testing requirement imposed under the USDA’s Interim Rules. CBN strains, however, may not afford the same advantage, given most growers’ inability to cultivate CBN-rich strains. Nevertheless, technologies that convert CBD and THC into CBN are beginning to emerge. This technological change will create a new set of legal issues. For instance, some commentators believe that THC-derived CBN may be treated as an illegal substance under the Federal Analogue Act (FAA). The FAA provides that any substance “substantially similar” to a Schedule 1 controlled substance should also be treated as a Schedule 1 substance. However, this theory is purely speculative and remains to be tested in a court of law.
Similarly to CBD-infused foods and dietary supplements, CBG and CBN products fall under the jurisdiction of the FDA. This is because the 2018 Farm Bill expressly preserves the agency’s authority to regulate products containing cannabis or cannabis-derived compounds under the Food, Drug and Cosmetic Act (the FDCA) and Section 351 of the Public Health Service Act.
CBG and CBN, unlike CBD, have not been approved or investigated by the FDA as new drug ingredients, which means the Drug Exclusion Rule should not apply to these two lesser-known cannabinoids. Indeed, the Drug Exclusion Rule provides that any substance that has been approved or investigated by the FDA as a new drug cannot also be sold and marketed as a food or dietary supplement, unless the substance was sold and marketed as such before investigation. In the absence of the Drug Exclusion Rule, the question of whether CBG and CBN may be sold and marketed as a food or a dietary supplement depends on whether these cannabinoids are safe for human consumption.
Under the FDCA, any ingredient found in a food sold and marketed in interstate commerce is subject to FDA premarket approval, unless the substance is generally recognized as safe (GRAS). A substance is considered GRAS if it is proven to be safe among experts qualified by scientific training and experience to evaluate its safety under the conditions of its intended use.
Although the FDA has determined three hemp seed ingredients, namely hulled hemp seed, hemp seed protein powder, and hemp seed oil, to be GRAS, the agency has yet to make the same determination for CBD and other cannabinoids. This means that until the FDA explores the safety of these cannabinoids, any CBG- or CBN-infused food sold and marketed in interstate commerce will violate the FDCA.
Pursuant to Section 413 of the FDCA (21. U.S.C. 450b), any dietary supplement that contains a new ingredient — an ingredient not found in a dietary supplement sold and marketed before October 15, 1994 –- must notify the FDA about that ingredient prior to marketing, and provide the agency with information that is the basis on which the manufacturer or distributor has concluded that their product will reasonably be expected to be safe under the conditions recommended or suggested in the labeling. If the manufacturer or distributor receives a no-objection letter from the FDA, or no response at all, they may lawfully market their dietary supplement after the 75-day notification period is over, so long as their scientific evidence of safety is reliable.
Lastly, as for any CBD products, manufacturers and distributors of CBG and CBN-infused foods and dietary supplements should steer clear of any medical claims about the therapeutic values of their products. Doing so would suggest that the products’ intended use is that of a drug, and thus, would violate the FDCA and warrant FDA enforcement actions.
To conclude, given the limited amount of studies on the effects of CBG and CBN, the sale and marketing of these products remains risky under the FDCA. Nevertheless, as reliable scientific research continues to grow, it will give these two lesser-known cannabinoids a viable legal runway in the food and dietary supplement market.
Nathalie Bougenies practices in the Portland office of Harris Bricken and was named a “2019 Rising Star” by Super Lawyers Magazine, an honor bestowed on only 2.5% of eligible Oregon attorneys. Nathalie’s practice focuses on the regulatory framework of hemp-derived CBD (“hemp CBD”) products. She is an authority on FDA enforcement, Food, Drug & Cosmetic Act and other laws and regulations surrounding hemp and hemp CBD products. She also advises domestic and international clients on the sale, distribution, marketing, labeling, importation and exportation of these products. Nathalie frequently speaks on these issues and has made national media appearances, including on NPR’s Marketplace. Nathalie is also a regular contributor to her firm’s Canna Law Blog.
Love ATL? Let’s make it official.
Sign up for our newsletter.